Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;149(7):3131-3137.
doi: 10.1007/s00432-022-04216-6. Epub 2022 Jul 23.

Advantages of organ-sparing treatment approaches in metastatic kidney cancer

Iurii Vitruk  1 , Oleg Voylenko  1 , Oleksandr Stakhovsky  1 , Oleksii Kononenko  1 , Maksym Pikul  2 , Sofiya Semko  1 , Bohdan Hrechko  1 , Denis Koshel  1 , Eduard Stakhovsky  1
Affiliations

Advantages of organ-sparing treatment approaches in metastatic kidney cancer

Iurii Vitruk et al. J Cancer Res Clin Oncol. 2023 Jul.

Abstract

Purpose: This study analyzed oncological outcomes of patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with cytoreductive partial nephrectomy or nephrectomy.

Methods: This prospective non-randomized cohort study included 109 patients with metastatic ccRCC who underwent surgical treatment between 2011 and 2020. Patients were stratified into cytoreductive partial nephrectomy or nephrectomy groups. Survival curves were estimated, and Cox-regression analysis was performed to identify factors affecting potential lethality.

Results: The groups differed significantly in terms of T stage and International metastatic RCC database consortium (IMDC) risk groups, but not international society of urological pathology (ISUP) grading. The average blood loss volume was higher in the partial nephrectomy group. In contrast, the duration of post-operative stay, complication rate; and 30-day hospital readmission rate were similar between two groups. There was a significant difference in overall survival in favor of the partial nephrectomy group, who had better 7-year survival rates. Standardization based on the clinical complexity of the patients showed that cytoreductive partial nephrectomy was associated with a lower risk of death compared to nephrectomy.

Conclusion: Partial nephrectomy is a safe method of choice in patients with metastatic ccRCC. Kidney preservation in a metastatic setting can play a role in reducing potential adverse systemic therapy events and in decreasing the risk for concomitant pathology deterioration.

Keywords: Cytoreductive nephrectomy; Cytoreductive partial nephrectomy; Metastatic renal cell carcinoma; Organ sparing management; Remaining functioning parenchyma volume; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

Figures

Fig.1
Fig.1
Survival curves of patients undergoing cytoreductive nephrectomy and cytoreductive partial nephrectomy
Fig. 2
Fig. 2
Survival curves of patients undergoing cytoreductive nephrectomy and cytoreductive partial nephrectomy after standardization by key parameters
See this image and copyright information in PMC

References

    1. Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ (2014) Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res 34:2405–2411 - PubMed
    1. Barbastefano J, Garcia JA, Elson P et al (2010) Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int 106:1266–1269. 10.1111/j.1464-410X.2010.09323.x - PubMed
    1. Barlow LJ, Korets R, Laudano M, Benson M, McKiernan J (2010) Predicting renal functional outcomes after surgery for renal cortical tumours: A multifactorial analysis. BJU Int 106:489–492. 10.1111/j.1464-410X.2009.09147.x - PubMed
    1. Bex A, Mulders P, Jewett M et al (2019) Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The SURTIME randomized clinical trial. JAMA Oncol 5:164–170. 10.1001/jamaoncol.2018.5543 - PMC - PubMed
    1. Bhindi B, Abel EJ, Albiges L et al (2019) Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol 75:111–128. 10.1016/j.eururo.2018.09.016 - PubMed

LinkOut - more resources